Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review

RATIONALE: Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence. PATIENT CONCERNS: Informed consent of the patients and their families. DIAGNOSES: Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Huifang, Yao, Yushuang, Yang, Hongjuan, Ma, Dehua, Chen, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758175/
https://www.ncbi.nlm.nih.gov/pubmed/29390473
http://dx.doi.org/10.1097/MD.0000000000009223
Descripción
Sumario:RATIONALE: Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence. PATIENT CONCERNS: Informed consent of the patients and their families. DIAGNOSES: Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer). INTERVENTIONS: the patient was treated with Megestrol Acetate Dispersible Tablets (trade name Yilizhi), 160 mg, orally, once daily, without interruption. OUTCOMES: The patient has been treated with progesterone therapy for stable conditions and her survival time is already roughly a decade (December 2006–October 2016). LESSONS: Hormone therapy may as a long-term management for hormone receptor-positive patients with recurrent endometrial cancer.

Ejemplares similares